Star51 Capital announced the first close of its inaugural medtech venture fund on June 11, 2026. The NYC-based platform is anchored by Abbott and Mayo Clinic and structured as an operator-led ecosystem fund.

Key facts

• Firm: Star51 Capital
• Date announced: June 11, 2026
• Fund: Fund I (first close; size undisclosed)
• Focus: Medtech + AI convergence
• Stage: Early and growth-stage
• Geography: U.S., Europe, Middle East sourcing
• Platform: Proprietary AI tool StarVision™

Leadership

• Adam Rosenwach — Founding MP; senior roles at Coridea, Deerfield Catalyst
• Tal Wenderow — Founding MP; founded Corindus Vascular Robotics (acquired by Siemens Healthineers for $1.1B)
• Raymond W. Cohen — Operating Partner; $5B+ in exit value as Medtech CEO/Chairman
• Scott Pantel — Operating Partner; Founder/CEO of LSI (global medtech ecosystem access)
• Joe Mullings — Operating Partner; Chairman/CEO of The Mullings Group

Why this matters

Star51 is not a traditional VC fund — it’s an ecosystem fund where operator LPs invest their own capital alongside strategics. Abbott and Mayo Clinic provide clinical validation and commercialization pathways beyond capital. The model targets the medtech inflection point where AI reshapes device design, delivery, and personalization.

Sources

1. PR Newswire (June 11, 2026): https://www.prnewswire.com/news-releases/star51-capital-announces-first-close-of-medtech-venture-fund-302798225.html
2. Everything Startups profile: https://www.everythingstartups.com/vc-funds/star51-capital